AMINOBOL M-5862

Item Code: AMINOBOL30ML
Price:  $175.00
Was: $200.00

AMINOBOL M-5862

Item Code: AMINOBOL30ML
Price:  $175.00
Was: $200.00

M-5862


Description: Methylester Kyseliny-anthranilove is an aryl hydrocarbon which modulates the androgen receptor. Liquid SARM
Concentration: 50mg per ml
Substantively: 24 hours
Organoleptic: Fruit initiation through to mint finish
Use: SARM and Anti-androgen; pushes androgen receptor activity to anabolic activity.
Active Ingredients: Methylester Kyseliny-anthranilove 50mg per ml
Application: 1ml daily with food in the morning.
Ingredients: Propylene Glycol, Methylester Kyseliny-anthranilove and flavour.
Elimination: Anthranilate esters have an average of 7-hour half-lives. Metabolised in liver.
Legal Status: Legal in Australia, food additive, FEMA

 

M-5862 is a non-steroidal compound designed to prevent muscle wasting, promote muscle growth and increase muscle and bone strength. After binding to receptors, M-5862 increases protein synthesis and anabolic activity, resulting in muscle hypertrophy and healing, mimicking the action of testosterone on muscles and joints. Unlike traditional androgenic steroids M-5862 does not lead to any of the associated side effects such as suppression of testosterone or increase in estrogen, making M-5862 desirable for this reason. Having anti-catabolic action’s, it prevents muscle wastage enabling the individual to hold lean muscle that is gained while trying to drop body fat. 

 

Key points:

• INCREASED STRENGTH
• INCREASE LEAN MUSCLE GAIN
• INCREASED BONE DENSITY
• INCREASED RECOVERY AND HEALING

 

Research Evidence & Efficacy


Roell, D., Rösler, T. W., Degen, S., Matusch, R., & Baniahmad, A. (2011). Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation. Chemical biology & drug design, 77(6), 450-459.
2 Negro-Vilar, A. (1999). Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. The Journal of Clinical Endocrinology & Metabolism, 84(10), 3459-3462.
3 Yin, D., Gao, W., Kearbey, J. D., Xu, H., Chung, K., He, Y., ... & Dalton, J. T. (2003). Pharmacodynamics of selective androgen receptor modulators. Journal of Pharmacology and Experimental Therapeutics, 304(3), 1334-1340.
4 https://tga-search.clients.funnelback.com/s/search.html?query=&collection=tga-artg
5 Gill, A. (2017). Standard for the uniform scheduling of medicines and poisons: The Poisons Standard 2017. Australian Government–Department of health and aging: Therapeutic Goods Administration, Canberra.

 

Research Evidence & Efficacy


6 Nickols, N. G., & Dervan, P. B. (2007). Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proceedings of the National Academy of Sciences, 104(25), 10418-10423.
7 Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002). Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. Journal of Biological Chemistry, 277(29), 26321-26326.
8 Sieber, P. R., Keiller, D. L., Kahnoski, R. J., Gallo, J., & Mcfadden, S. (2004). Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. The Journal of urology, 171(6), 2272-2276.
9 Schellhammer, P. F. (2002). An evaluation of bicalutamide in the treatment of prostate cancer. Expert opinion on pharmacotherapy, 3(9), 1313-1328.
10 Roell, D., Rösler, T. W., Degen, S., Matusch, R., & Baniahmad, A. (2011). Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation. Chemical biology & drug design, 77(6), 450-459.